Bianchi S, Paglierani M, Zampi G, Cardona G, Cataliotti L, Bonardi R, Ciatto S
University Institute of Anatomia e Istologia Patologica, Florence, Italy.
Br J Cancer. 1993 Mar;67(3):625-9. doi: 10.1038/bjc.1993.114.
The prognostic value of c-erbB-2 oncogene expression was studied retrospectively in a consecutive series of 230 node negative breast cancers, followed-up for at least 7 years after primary treatment. The expression of c-erbB-2 oncoprotein was determined on formalin-fixed paraffin-embedded tissue, using a monoclonal anti-c-erbB-2 antibody by the avidin-biotin immunoperoxidase method. Positive immunostaining was observed in 20.9% of cases, whereas strong diffuse positivity was recorded only in 8.7% of cases. C-erbB-2 gene product showed no association to T category or nuclear grade. A significant association of c-erbB-2 expression to prognosis was observed only for cases showing a strong diffuse immunostaining, but such an association was no longer statistically significant at multivariate analysis adjusting for other prognostic factors such as T category and nuclear grading. C-erbB-2 expression is of no value to predict the clinical course of node negative patients in the current practice.
对连续230例淋巴结阴性乳腺癌患者进行回顾性研究，以探讨c-erbB-2癌基因表达的预后价值，这些患者在接受初始治疗后至少随访了7年。采用抗生物素蛋白-生物素免疫过氧化物酶法，使用单克隆抗c-erbB-2抗体，在福尔马林固定石蜡包埋组织上测定c-erbB-2癌蛋白的表达。20.9%的病例观察到阳性免疫染色，而仅有8.7%的病例记录到强弥漫性阳性。c-erbB-2基因产物与T分类或核分级无关。仅在显示强弥漫性免疫染色的病例中观察到c-erbB-2表达与预后有显著关联，但在对T分类和核分级等其他预后因素进行多变量分析调整后，这种关联不再具有统计学意义。在目前的实践中，c-erbB-2表达对预测淋巴结阴性患者的临床病程没有价值。
